{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/67105af848726944170ab1fe/69001bb9594b659111a8f9fb?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Michael Langer: Biotech Investing in the Data Age","description":"<p>If you work in biotech, the name Langer likely rings a bell. Robert Langer—the MIT legend behind Moderna and dozens of biotech startups—has become synonymous with innovation. Now, a new Langer is stepping forward. Michael Langer, Robert’s son, represents a new generation of investors rethinking biotech in the age of AI and data. Rather than chasing hype, he’s applying lessons from a lifetime around scientists to build a more disciplined, informed investment philosophy. As co-founder of T.Rx Capital, he’s helping shape the next phase of tech-enabled biotech—and exploring what truly drives success in precision medicine.</p><p><br></p><p>Produced and hosted by Jonathan D. Grinstein, PhD</p><p>Audio mixed and mastered by David Mosely</p><p>Brought to you by Inside Precision Medicine (SAGE Publishing)</p>","author_name":"Inside Precision Medicine"}